Condition: Prostate Cancer · Sponsor: The Netherlands Cancer Institute
An extended pelvic lymph node dissection (ePLND) is the most accurate staging method to assess the presence of lymph node metastases in prostate cancer (PCa) patients. The therapeutic value, however remains unclear. Prospective randomized trials to address this void are lacking. Since in intermediate and a proportion of high risk PCa the risk of nodal metastases is generally below 25%, the vast majority of men undergo a procedure that has no oncological benefit, but is not without toxicity. Therefore, the investigators aim to compare the oncologic outcomes of intermediate- and high-risk PCa patients with an estimated risk of lymph node invasion of 5-20% undergoing a radical prostatectomy (RP) with or without an ePLND.
This description comes directly from the study's public registry record.
Henk G van der Poel, Prof · 0205129111 · h.vd.poel@nki.nl
Hilda A de Barros, MD · 0205129111 · h.d.barros@nki.nl
Always discuss trial participation with your own doctor first.
| NKI-AVL | Amsterdam, Netherlands | Recruiting |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.